1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2014
-
Mark
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
(
- Contribution to journal › Article
- 2009
-
Mark
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
(
- Contribution to journal › Letter
- 2007
-
Mark
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer
(
- Contribution to journal › Article